{"filings":[{"id":1508522,"accession_number":"0001193125-26-298004","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2026-07-08T12:00:15+00:00","items":["1.02"],"status":"ready","headline":"Alkermes terminates authorized generic VIVITROL supply agreement with Amneal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement dated Sept 9, 2025, for Amneal to distribute authorized generic VIVITROL in the US.","Terminated July 6, 2026, after Amneal failed to meet certain terms and declined to order batches.","No penalties incurred; both parties released all claims related to the agreement.","No further payments or obligations owed by either party under the terminated agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1038558,"accession_number":"0001193125-26-270280","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2026-06-15T11:09:44+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Alkermes announces orphan drug designations for alixorexton in US for IH and EU for narcolepsy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants orphan drug designation to alixorexton for idiopathic hypersomnia.","European Commission grants orphan drug designation to alixorexton for narcolepsy.","Alixorexton is an oral OX2R agonist in phase 3 for narcolepsy and phase 2 for IH.","ODD provides market exclusivity (7 yrs US, 10 yrs EU) if approved.","Alixorexton previously received FDA Breakthrough Therapy for NT1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554519,"accession_number":"0001193125-26-232584","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2026-05-20T20:10:47+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve increase in Alkermes equity plan by 5.9M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At May 20 AGM, shareholders approved amendment to 2018 Stock Option and Incentive Plan, increasing authorized shares by 5,900,000.","All nine director nominees elected; advisory vote on executive compensation passed with ~98% support.","Ratification of PwC as independent auditor approved; board authority renewed under Irish law.","The amended plan allows issuance of up to 59.35M shares plus prior plan shares; full vesting minimum one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22283,"accession_number":"0001193125-26-218150","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2026-05-12T11:07:58+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"LUMRYZ meets all primary, key secondary endpoints in Phase 3 idiopathic hypersomnia study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint ESS showed statistically significant improvement vs placebo (p<0.0001).","Key secondary endpoints PGI-C and IHSS also met with p<0.0001.","Safety profile consistent with known LUMRYZ safety; common AEs included nausea, headache.","Alkermes plans to file sNDA with FDA by end of 2026 for IH indication.","Settlement agreement restricts marketing of LUMRYZ for IH until March 1, 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93380,"accession_number":"0001193125-26-205008","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alkermes Q1 revenue $392.9M; GAAP net loss $66.5M after Avadel acquisition costs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenues $392.9M, up 28% YoY; GAAP net loss $66.5M vs. income of $22.5M in Q1 2025.","Adjusted EBITDA $80.3M, up from $45.6M YoY; LUMRYZ contributed $39.5M post-Avadel close on Feb 12.","Full-year 2026 GAAP net loss guidance improved to ($70)-($90)M from ($115)-($135)M; total revenue outlook unchanged.","Avadel acquisition closed in Feb; used $775M cash and $1.525B term loans; cash balance now $538M.","Initiated Phase 3 Brilliance studies for alixorexton in narcolepsy type 1 and type 2."],"consensus_eps_estimate":-0.5786,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":392911000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93379,"accession_number":"0001193125-26-201657","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K/A","filed_at":"2026-05-01T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Alkermes completes Avadel acquisition; pro forma net income $13.8M, EPS $0.08","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Feb 12, 2026; total cash consideration $21.00 per Avadel share plus CVR up to $1.50 per share.","Financed with $1.525B in new debt: $750M TLA + $775M TLB facilities.","Pro forma combined revenue $1.755B, net income $13.8M, diluted EPS $0.08 for year ended Dec 31, 2025.","Preliminary purchase price allocation: $1.795B intangible assets, $429.6M goodwill, $107.7M contingent consideration.","Avadel contributed $279.1M product sales and $64.7M net income in its fiscal year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104952,"accession_number":"0001193125-26-068927","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Alkermes CEO Richard Pops to retire July 31, 2026; COO Blair Jackson named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Pops retires as CEO effective July 31, 2026, after 35-year tenure; will remain Chairman and Senior Advisor through Dec 31, 2026.","Blair Jackson, current EVP/COO, appointed CEO effective Aug 1, 2026; Jackson has over 25 years experience at Alkermes.","Pops receives $75k/month advisory retainer, pro-rated FY2026 bonus at target, $2.69M RSU grant vesting Dec 31, 2026, and $40k Chairman retainer.","Outstanding equity awards continue vesting post-retirement; post-termination exercise periods extended up to 21 months.","Company cites ~$1.5B annual revenue, ~2,000 employees, and alixorexton's Breakthrough Therapy designation for narcolepsy type 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104951,"accession_number":"0001193125-26-068512","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alkermes: FY2025 revenue $1.48B, GAAP EPS $1.43; 2026 guidance shows net loss from Avadel deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $1.48B in 2025; proprietary net sales up ~9% to $1.18B; LYBALVI grew 22% in Q4.","GAAP net income $242M ($1.43 dil EPS) vs $367M in 2024; Q4 net income $49.3M.","Closed Avadel acquisition Feb 12, 2026; used $775M cash + $1.525B term loans; expects ~$150M inventory step-up expense.","2026 guidance: revenue $1.73-1.84B, GAAP net loss $(115)-$(135)M, adjusted EBITDA $370-410M.","Alixorexton Phase 3 for narcolepsy to start Q1 2026; advancing orexin pipeline for ADHD and fatigue."],"consensus_eps_estimate":0.3492,"consensus_eps_actual":1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":1475899000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104950,"accession_number":"0001193125-26-047682","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["1.01","1.02","2.01","2.03","7.01","9.01"],"status":"ready","headline":"Alkermes closes Avadel acquisition for $21/share cash + CVR; funded with $1.525B term loans","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Consideration: $21.00/sh cash plus one non-transferable CVR (potential $1.50/sh) per Avadel share.","Closed Feb 12, 2026; Avadel shares delisted from Nasdaq.","Financed with $1.525B term loans (due 2031) and ~$750M cash; $1.5B in LUMRYZ IP to be amortized over 13 years.","Expected accretive in 2026; FY 2026 guidance on Feb 25; Q1 costs $40M, $180M inventory step-up expensed as COGS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104949,"accession_number":"0001193125-26-009813","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Alkermes discloses preliminary FY2025 total revenue at J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation includes estimated total revenues for year ended Dec. 31, 2025, which are preliminary and unaudited.","No specific revenue figures or other financial details available in the furnished exhibit text.","Investors advised to await final audited financials; conference presentation may contain additional context."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104948,"accession_number":"0001193125-26-003453","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Alkermes gets FDA Breakthrough Therapy designation for alixorexton in narcolepsy type 1","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy designation based on phase 1/2 data including Vibrance-1 study (n=92).","Phase 2 met primary endpoint with dose-dependent improvements in wakefulness vs placebo.","Alkermes plans to initiate alixorexton global phase 3 program in Q1 2026.","Alixorexton is an investigational oral selective orexin 2 receptor agonist for NT1, NT2, and IH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121207,"accession_number":"0001193125-25-286909","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Alkermes raises Avadel offer to $21.00 cash plus $1.50 CVR per share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash consideration raised to $21.00/share from $18.50; CVR of $1.50/share unchanged.","Total enterprise value up to ~$2.37B if CVR milestone achieved.","Avadel board determined Alkermes' increased offer superior to Lundbeck's competing bid.","Bridge credit facility expanded to $1.513B to fund cash consideration and fees.","Closing still expected in Q1 2026, subject to approvals and conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121206,"accession_number":"0001193125-25-276161","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Alkermes' alixorexton meets dual primary endpoints in Phase 2 narcolepsy type 2 study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Alixorexton (10, 14, 18 mg) showed statistically significant improvements vs placebo on MWT and ESS at week 8.","14 mg and 18 mg doses achieved statistical significance on MWT (p<0.05); 18 mg dose on ESS (p<0.05).","Drug was generally well tolerated; most common TEAEs were pollakiuria, insomnia, urinary urgency, dizziness, headache.","No serious TEAEs, no safety signals in hepatic, renal, vitals, ECGs, or ophthalmic exams.","Phase 3 program for narcolepsy type 1 and type 2 expected to initiate in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121205,"accession_number":"0001193125-25-252207","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alkermes Q3 revenue $394.2M, GAAP EPS $0.49; raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenues $394.2M up 4% YoY; proprietary net sales $317.4M up 16% YoY.","LYBALVI sales $98.2M (+32% YoY); ARISTADA $98.1M (+16% YoY); VIVITROL $121.1M (+7% YoY).","GAAP net income $82.8M vs $92.4M in Q3 2024; diluted EPS $0.49.","FY2025 revenue guidance raised to $1.43-1.49B from $1.34-1.43B; GAAP net income now $230-250M.","CEO highlighted proposed Avadel acquisition and positive phase 2 data for alixorexton in narcolepsy."],"consensus_eps_estimate":0.3066,"consensus_eps_actual":1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":1091352000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121204,"accession_number":"0001193125-25-245852","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["1.01","2.02","2.03","7.01","9.01"],"status":"ready","headline":"Alkermes to acquire Avadel for $18.50/share plus up to $1.50 CVR; $1.23B bridge financing arranged","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash consideration of $18.50 per Avadel share; CVR for additional $1.50 upon FDA approval of LUMRYZ and legal settlement.","Bridge term loan of up to $1.23B from JPMorgan to fund the cash consideration and fees; margin 3% SOFR + step-up.","Acquisition subject to Avadel shareholder vote, Irish High Court sanction, and US antitrust clearance; expected to close in Q1 2026.","Avadel equity awards to be canceled for cash and CVRs; stock options with exercise price ≥ $18.50 cancelled for no consideration.","Alkermes reported cash and total investments of $1.1B as of Sept 30, 2025 per investor presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137853,"accession_number":"0001193125-25-202307","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"Alkermes sues Teva, Apotex, MSN over LYBALVI patents; enters VIVITROL AG deal with Amneal","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed patent lawsuits against Teva (8/15), Apotex (8/27), MSN (9/5) over generic LYBALVI; 30-month FDA stays triggered.","LYBALVI patents expiring 2032-2041; lawsuit amended 8/20 to include additional patent.","Entered authorized generic supply agreement with Amneal for VIVITROL, effective upon third-party ANDA launch.","Amneal may distribute AG VIVITROL for one year, supply limited to ~15% of 2024 unit sales; profit sharing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137852,"accession_number":"0001193125-25-201840","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Alkermes appoints Joshua Reed as CFO effective September 15, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Reed will report to CEO Richard Pops and join the management committee.","He brings 30+ years finance experience; most recently CFO of Omega Therapeutics and Aldeyra Therapeutics, and earlier at Bristol Myers Squibb.","Base salary $615,000, target annual cash bonus 50% of base, new-hire equity grant valued at $3.5 million.","Blair C. Jackson, EVP/COO, had been serving as interim principal financial officer; Samuel Parisi remains interim principal accounting officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137851,"accession_number":"0000950170-25-113379","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alkermes' alixorexton meets primary endpoint in phase 2 NT1 study; all doses improve wakefulness","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: MWT mean sleep latency improved by 22.2-26.0 min vs placebo -0.6 min (p<0.01 all doses).","ESS score normalized (-6.4 to -8.7 vs placebo -3.1, p<0.01); cataplexy rate reduced (6mg p=0.01).",">40% of 6mg/8mg patients had 100% cataplexy reduction at week 6; improvements in fatigue/cognition.","No serious TEAEs; common mild-moderate events: pollakiuria, insomnia, salivary hypersecretion, blurred vision.","Global phase 3 program for alixorexton in NT1 to begin Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137850,"accession_number":"0000950170-25-099382","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alkermes Q2 revenue $390.7M, GAAP EPS $0.52; product sales grow 14% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q2 revenues $390.7M (-2% YoY); GAAP net income $87.1M, diluted EPS $0.52.","Proprietary net sales $307.2M (+14% YoY): LYBALVI $84.3M (+18%), ARISTADA $101.3M (+18%), VIVITROL $121.7M (+9%).","Adjusted EBITDA $126.5M; cash & investments $1.05B at June 30, 2025.","Company reaffirms 2025 financial expectations.","R&D spend $77.4M (+30% YoY) on alixorexton; positive Vibrance-1 phase 2 results support global phase 3."],"consensus_eps_estimate":0.3887,"consensus_eps_actual":0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":697167000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137849,"accession_number":"0000950170-25-097323","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alkermes reports positive phase 2 results for alixorexton in narcolepsy type 1; primary endpoint met","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Alixorexton met primary endpoint: statistically significant and dose-dependent improvements in wakefulness (MWT) vs placebo (p<0.0001 at all doses).","Key secondary: ESS improved significantly at all doses (p<0.0001); weekly cataplexy rates numerically improved, significant at 6 mg (p=0.005).","Exploratory endpoints: alixorexton improved disease severity (NSS), cognition (BC-CCI), and fatigue (PROMIS-Fatigue) at all doses (p<0.01).","Alixorexton was generally well tolerated; no serious AEs; >95% of patients entered open-label extension.","Data support rapid initiation of global phase 3 program in NT1; detailed results at World Sleep Congress Sept 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155234,"accession_number":"0000950170-25-075783","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Alkermes shareholders approve 4.25M share increase under 2018 stock plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected; advisory say-on-pay approved 143.3M for vs 1.9M against.","Ratification of PwC as auditor approved 152.6M for; board authority to allot shares renewed.","Amendment to 2018 Stock Option and Incentive Plan adding 4,250,000 shares approved (127.0M for, 18.3M against).","Authority to disapply statutory pre-emption rights under Irish law renewed (149.7M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155233,"accession_number":"0000950170-25-061441","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alkermes Q1 2025 revenue $306.5M, GAAP EPS $0.13; reaffirms 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $306.5M, down from $350.4M in Q1 2024; GAAP net income $22.5M ($0.13 diluted EPS).","Proprietary net sales $244.5M (+5% YoY); LYBALVI grew 23% to $70.0M, VIVITROL $101.0M, ARISTADA $73.5M.","Cash and investments $916.2M, up from $824.8M at Dec. 31, 2024.","ALKS 2680 phase 2 Vibrance-1 enrollment complete; topline data expected early Q3 2025.","Company reiterates full-year 2025 financial expectations as communicated Feb. 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":306510000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155232,"accession_number":"0000950170-25-054483","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Alkermes CFO Iain M. Brown passes away; interim leadership continues","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Iain M. Brown died on April 14, 2025, after a battle with cancer; on medical leave since Feb. 2024.","Blair C. Jackson (EVP, COO) and Samuel J. Parisi (VP, Finance) continue as interim principal financial and accounting officers.","Company will search for a permanent CFO successor; interim roles remain unchanged.","Brown served 22 years at Alkermes; board and management express condolences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173748,"accession_number":"0000950170-25-018402","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alkermes reports FY2024 revenue $1.56B, net income $372M; guides FY2025 rev $1.34-$1.43B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 total revenues $1.56B, proprietary net sales up 18% YoY to $1.08B; GAAP diluted EPS from cont. ops $2.20.","Q4 proprietary net sales $307.7M: LYBALVI $77M (+37%), ARISTADA $96.6M (+16%), VIVITROL $134.1M (+31%).","Year-end cash/investments $824.8M; debt-free after retiring $290M debt; repurchased $200M shares in 2024.","FY2025 guidance: rev $1.34-$1.43B, GAAP net income $175-$205M, R&D spend up to $335M for pipeline.","ALKS 2680 Phase 2 narcolepsy data expected H2 2025; Phase 2 in idiopathic hypersomnia planned; ALKS 4510/7290 Phase 1 starts."],"consensus_eps_estimate":null,"consensus_eps_actual":2.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":1557632000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173747,"accession_number":"0000950170-25-004600","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Alkermes provides preliminary 2024 cash and investments estimate at JPM Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Alkermes presented at J.P. Morgan Healthcare Conference on Jan 15, 2025.","Included current expectation of cash and investments for year ended Dec 31, 2024.","No specific cash/investment figures disclosed in the filing or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190730,"accession_number":"0000950170-24-138478","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Alkermes prepays and terminates Amended and Restated Credit Agreement; no early termination penalties","summary_kind":"llm","event_type":"debt","confidence":"medium","bullets":["Dec 19, 2024: Alkermes, Inc. subsidiary prepaid all outstanding amounts under Credit Agreement and terminated it.","No early termination penalties incurred beyond customary breakage costs.","All liens on collateral securing the Credit Agreement obligations were released.","Credit Agreement originally dated Sep 16, 2011, amended multiple times through June 28, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190729,"accession_number":"0000950170-24-132303","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alkermes releases updated corporate presentation; no new financial data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["December 2, 2024: Alkermes made available an updated corporate presentation.","Presentation titled 'Alkermes 2024: Profitable, Pure-play Neuroscience Company'.","No new financial guidance, pipeline updates, or product launches were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190728,"accession_number":"0000950170-24-116848","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alkermes Q3 2024: proprietary net sales up 18% YoY to $273M; GAAP EPS $0.56","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $378.1M vs $380.9M YoY; proprietary net sales $273M (+18% YoY).","LYBALVI sales $74.7M (+47%), VIVITROL $113.7M (+14%), ARISTADA $84.7M.","GAAP net income from continuing ops $92.8M, diluted EPS $0.56; non-GAAP net income $121.4M.","Cash & investments $927.8M; repurchased 4.4M shares for $115.6M in Q3; $200M remaining under buyback.","Company reiterates 2024 financial expectations; advancing ALKS 2680 phase 2 studies in narcolepsy."],"consensus_eps_estimate":null,"consensus_eps_actual":1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":1127646000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190727,"accession_number":"0000950170-24-113740","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alkermes hosts investor event to review orexin portfolio and development strategy","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation reviewed Alkermes' orexin portfolio on October 9, 2024.","No specific financial or clinical data disclosed in the furnished exhibit.","Investor event focused on development strategy for orexin programs.","Filing under Item 7.01 (Regulation FD) with presentation as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207206,"accession_number":"0000950170-24-085860","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alkermes Q2 2024 GAAP EPS $0.55; proprietary sales up 16% YoY; reiterates guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $399.1M, GAAP net income from continuing ops $94.7M; non-GAAP net income $123.4M.","Proprietary net sales $269.3M (+16% YoY); LYBALVI $71.4M (+52%), VIVITROL $111.9M (+10%).","Cash & investments $962.5M; repurchased 3.5M shares for $84.7M in Q2; $315.3M remaining.","Positive phase 1b ALKS 2680 data in narcolepsy; initiated Vibrance-1 phase 2 for NT1.","Reiterated 2024 financial expectations; sold Athlone facility to Novo Nordisk for ~$91M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":749503000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224571,"accession_number":"0000950170-24-067296","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Alkermes shareholders approve 2018 equity plan amendment, elect directors at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2018 Stock Option and Incentive Plan increasing authorized shares by 6,300,000 and revising Sale Event provisions (138.6M for, 14.0M against).","All 11 director nominees elected with majority support; Richard F. Pops had lowest for votes (145.6M for, 6.6M against).","Advisory say-on-pay approved (149.8M for, 2.4M against); frequency set to annual (149.98M for 1 year).","Ratification of PricewaterhouseCoopers as independent auditor (158.3M for).","Renewal of Irish law authorities to allot shares and disapply pre-emption rights approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224570,"accession_number":"0000950170-24-050887","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alkermes Q1 2024 revenue $350.4M, GAAP net income $38.9M, LYBALVI sales up 50% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues of $350.4M vs $287.6M in Q1 2023; GAAP net income from continuing ops $38.9M ($0.23 EPS) vs loss of $12.1M.","LYBALVI net sales $57.0M (+50% YoY); VIVITROL $97.7M; ARISTADA $78.9M; royalty revenue $62.7M from J&J sublicense.","Non-GAAP net income from continuing ops $76.2M vs $30.1M; cash & investments $807.8M, debt $290.1M.","R&D expense $67.6M (+6%) driven by ALKS 2680; SG&A $179.7M (+7%) on LYBALVI DTC campaign.","Company reiterates 2024 financial expectations; positive phase 1b data for ALKS 2680 in narcolepsy type 2."],"consensus_eps_estimate":null,"consensus_eps_actual":0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":350372000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224569,"accession_number":"0000950170-24-042791","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ALKS 2680 shows statistically significant wakefulness improvement in NT2 and IH phase 1b","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ALKS 2680 improved mean sleep latency vs placebo at all doses in NT2 (5mg: +12 min, p<0.05; 12mg: +19 min, p<0.001; 25mg: +21 min, p<0.001).","In IH cohort, mean sleep latency improved by 8 min (5mg, p<0.05), 11 min (12mg, p<0.01), and 18 min (25mg, p<0.001).","No serious AEs or discontinuations; mild transient TEAEs including pollakiuria, insomnia, dizziness at highest dose.","Phase 2 study in narcolepsy type 2 planned for second half of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243869,"accession_number":"0000950170-24-027585","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Alkermes appoints Nancy S. Lurker to Board of Directors, increasing size to 11","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to 11 directors; Nancy S. Lurker elected effective March 5, 2024, term expiring at 2024 annual meeting.","Lurker brings decades of pharmaceutical/biotech leadership and commercial expertise; CEO highlights alignment with growth strategy.","She will receive standard new director equity grant and annual cash retainer; equity grants in April 2024 subject to re-election forfeiture.","Lurker not a party to any related-party transactions since Jan 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243868,"accession_number":"0000950170-24-015597","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alkermes reports 2023 total revenues $1.66B, GAAP EPS $2.10; guides 2024 EBITDA ~$445-485M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $355.8M vs loss of $158.3M in 2022; diluted EPS $2.10.","Proprietary net sales $920M (+18% YoY); LYBALVI grew to $191.9M (up 100% YoY).","2024 guidance: total rev $1.5-1.6B, GAAP net income $350-390M, non-GAAP net income $465-505M.","Board approved new $400M share repurchase program (no expiration date).","Oncology separation completed Nov 2023; Athlone facility sale to Novo Nordisk for $92.5M expected mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":2.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":1663405000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243867,"accession_number":"0000950170-24-011269","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alkermes appoints interim CFO and interim PAO during CFO's medical leave","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Blair C. Jackson, EVP & COO, named interim principal financial officer effective Feb 1, 2024.","Samuel J. Parisi, VP Finance, named interim principal accounting officer.","Iain M. Brown, CFO and PAO, on medical leave; appointments temporary until his return.","No material changes to compensation or indemnification arrangements.","Interim officers are internal appointees with no family relationships or conflicts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243866,"accession_number":"0000950170-24-002678","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alkermes to present at J.P. Morgan Healthcare Conference; highlights profitability and neuroscience focus","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation on Jan 10, 2024, titled 'Profitable, Pure-play Neuroscience Company'.","CEO Richard Pops to present at the 42nd Annual J.P. Morgan Healthcare Conference.","No specific financial or operational data disclosed in the excerpt provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261269,"accession_number":"0000950170-23-070190","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Alkermes sells Athlone facility to Novo Nordisk for $92.5M; 400 employees to transfer","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Asset sale of Athlone development and manufacturing facility for $92.5M cash; expected to close mid-2024.","Approximately 400 Alkermes employees at Athlone will transfer to Novo Nordisk upon closing.","Alkermes to enter subcontracting arrangements to continue certain work at facility through end of 2025; deal expected to be cost-neutral over that period.","Alkermes retains all royalty revenues from products currently manufactured at Athlone; continues producing VIVITROL, ARISTADA, LYBALVI at Wilmington, OH.","CEO Richard Pops: transaction expected to drive operational efficiencies and enhance profitability as Alkermes focuses on pure-play neuroscience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261268,"accession_number":"0000950170-23-069042","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Nancy J. Wysenski retires from Alkermes board; Board size reduced to 10","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nancy J. Wysenski notified retirement on Dec 4, 2023, effective Dec 8, 2023, after 10 years of service.","Board decreased size from 11 to 10 directors effective Dec 8, 2023.","Frank Anders Wilson appointed as Lead Independent Director, effective Dec 8, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261267,"accession_number":"0000950170-23-064005","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Alkermes completes spin-off of oncology business into Mural; raises 2023 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Nov 15, 2023, distributed 1 Mural share for every 10 Alkermes shares; MURA begins trading Nov 16.","FY2023 GAAP net income guidance raised to $250M–$280M from $225M–$265M; diluted EPS $1.46–$1.63.","Non-GAAP net income guidance raised to $270M–$300M from $230M–$270M; diluted EPS $1.57–$1.75.","Alkermes capitalized Mural with $275M cash; now a pure-play neuroscience company.","Operating expenses expected to drop ~$20M in last six weeks of 2023 due to separation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261266,"accession_number":"0000950170-23-056978","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Alkermes sets Nov 6 record date, Nov 15 distribution for Mural Oncology spin-off (1:10 ratio)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Form 10 declared effective by SEC for Mural Oncology spin-off.","Record date set as Nov 6, 2023; distribution date Nov 15, 2023.","Shareholders receive one Mural share per ten Alkermes shares held.","When-issued trading for MURA under 'MURAV' and ALKS ex-distribution under 'ALKSV' expected.","Mural Oncology to trade on Nasdaq under 'MURA' from Nov 16, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261265,"accession_number":"0000950170-23-056057","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Alkermes sets Nov 6 record date for Mural Oncology spin-off distribution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board set Nov 6, 2023 as record date for distribution of Mural ordinary shares to Alkermes shareholders.","No shareholder action required to receive Mural shares.","Distribution subject to SEC declaring Form 10 effective and Mural listing on Nasdaq.","Mural is the oncology business being separated into an independent public company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261264,"accession_number":"0000950170-23-054999","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alkermes Q3 2023 revenue $380.9M, GAAP net income $47.8M; reiterates FY guidance; oncology split in Nov","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q3 revenues $380.9M vs $252.4M YoY; proprietary product sales up 16% to $231.8M.","GAAP net income $47.8M ($0.28 diluted EPS) vs GAAP net loss of $64.0M YoY; non-GAAP net income $109.5M ($0.64 diluted EPS).","LYBALVI net sales $50.7M (+87% YoY); VIVITROL $99.3M (+3%); ARISTADA $81.8M (+8%).","Cash & investments $995.6M; debt $291.4M; reiterates FY2023 guidance.","Expects oncology spin-off (Mural) Nov 2023 with $275M; settled VIVITROL patent suit with Teva (generic Jan 2027)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":1285930000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261263,"accession_number":"0000950170-23-054504","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alkermes reports Phase 1 data for ALKS 2680 showing significant sleep latency improvement in narcolepsy type 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ALKS 2680 demonstrated dose-dependent improvement in sleep latency: +18, +30, +37 minutes vs placebo (-1 min) at 1, 3, 8 mg (p<0.01 to p<0.001).","At 8 mg dose, patients maintained wakefulness for full 40-minute MWT up to 10 hours post-dose.","ALKS 2680 generally well tolerated; mild AEs at 8 mg (insomnia, pollakiuria, salivary hypersecretion); no serious AEs.","PK profile supports once-daily oral dosing; Phase 2 study planned for H1 2024.","First cohort (4 NT1 patients) data presented at World Sleep Congress; study also enrolling NT2 and IH patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278530,"accession_number":"0000950170-23-045176","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2023-08-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Alkermes settles VIVITROL patent litigation with Teva; generic entry January 2027","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Teva granted license to market generic VIVITROL in U.S. starting Jan 15, 2027, or earlier under certain circumstances.","Settlement resolves lawsuit filed Sep 2020; trial completed Mar 2023; patent expires 2029.","Agreement subject to FTC and DOJ review; parties will file joint stipulation to dismiss litigation.","Financial terms not disclosed; license is non-exclusive, royalty-free, limited to Teva's ANDA product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278529,"accession_number":"0000950170-23-034556","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alkermes Q2 2023 revenues $617.4M, GAAP net income $237.1M on arbitration win","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $617.4M including $248.4M back royalties from Janssen arbitration; proprietary product sales up 21% YoY to $231.5M.","GAAP net income $237.1M ($1.43 basic EPS) vs net loss $30.1M in Q2 2022; non-GAAP net income $94.3M ($0.57 EPS).","LYBALVI net sales $47.0M (+134% YoY); VIVITROL $102.1M (+6%); ARISTADA $82.4M (+10%).","Cash and investments $907.2M; FY 2023 financial expectations reiterated, including accretive INVEGA royalties.","Oncology separation into Mural Oncology on track for H2 2023; Caroline Loew appointed CEO designate."],"consensus_eps_estimate":null,"consensus_eps_actual":1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":904992000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278528,"accession_number":"0000950170-23-031901","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2023-07-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Alkermes shareholders approve 6.5M share increase to equity plan; Sarissa votes against own recommendations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 2018 Stock Option and Incentive Plan amendment, adding 6,500,000 shares.","All 6 management director nominees re-elected; dissident Sarissa withheld votes despite prior recommendation.","All company proposals passed: say-on-pay (115.9M for), auditor (142.6M for), share issuance authority.","Sarissa cast over 13 million votes contrary to its stated voting intent on plan, issuance, and pre-emption items.","Equity plan approval received 125.4M votes for and 21.3M against, including Sarissa's 13M+ no votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278527,"accession_number":"0000950170-23-031717","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Alkermes amends credit agreement to replace LIBOR with SOFR","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment dated June 28, 2023 to Credit Agreement originally dated Sept 16, 2011.","Interest rate benchmark transitions from LIBOR to SOFR with conforming changes.","No change to principal amount, maturity, or covenants mentioned.","Company will file full amendment with Q2 2023 Form 10-Q.","Administrative agent remains Morgan Stanley Senior Funding, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296721,"accession_number":"0000950170-23-026518","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Alkermes wins arbitration vs Janssen, raises 2023 outlook by ~$425M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Final arbitration award confirms Janssen must pay royalties on INVEGA and CABENUVA products; back royalties of ~$194M (incl. interest) received.","2023 total revenue guidance raised to $1.55B-$1.68B from $1.13B-$1.25B; GAAP net income now $225M-$265M vs prior loss.","Royalty terms clarified: INVEGA SUSTENNA until Aug 2024, INVEGA TRINZA until Q2 2030, INVEGA HAFYERA until May 2030, CABENUVA until Dec 2036.","Non-GAAP net income guidance raised to $230M-$270M from $0M-$40M; back royalties excluded from non-GAAP.","Company reiterates FY2024/2025 profitability targets (25%/30% non-GAAP net income margin) excluding Janssen royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296720,"accession_number":"0001564590-23-007080","cik":1520262,"company_name":"Alkermes plc.","ticker":"ALKS","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Alkermes files preliminary proxy; Board declines to endorse Sarissa's three nominees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed preliminary proxy for 2023 AGM; board has added 7 new independent directors since 2019.","Nominating Committee interviewed Sarissa's three nominees—Denner, Bonfiglio, Schlesinger—and did not endorse them.","Board reiterates openness to resolution with Sarissa after more than 30 engagements over multi-year period.","Current board comprises 4 independent directors appointed with shareholder support (Elliott and Sarissa).","Company cites strong recent share price outperformance vs. relevant peers and indices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6628697060.906275,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-05-08T23:59:59+00:00|296720"}